PharmNovo

PharmNovo's goal is to develop safe and effective novel Delta opioid receptor agonists for the treatment of chronic pain (DORAs). This is a significantly different objective from traditional opioids, which have already caused an epidemic of addiction and toxicity. The company addresses a significant unmet medical need for safe and effective chronic pain treatment, impacting up to 30% of the adult population in the United States and Europe. PharmNovo is developing a new approach to treating neuropathic pain, a difficult-to-treat type of pain that often progresses into a chronic condition. The company’s lead candidate drug, PN6047, is a novel compound derived from AstraZeneca’s cutting-edge research and is currently undergoing Phase 1 clinical evaluation.